Featured Publications
Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity
Zhang X, Halberstam A, Zhu W, Leitner B, Thakral D, Bosenberg M, Perry R. Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity. Cancer & Metabolism 2022, 10: 21. PMID: 36457136, PMCID: PMC9714036, DOI: 10.1186/s40170-022-00296-7.Peer-Reviewed Original ResearchTumor microenvironmentAnti-tumor immunityPotential prognostic factorsObesity-associated cancersPotential prognostic predictorPatient RNA-seq dataSubset of studiesImmunogenic tumorsCancer Genome AtlasLymphocyte infiltrationMelanoma cell linesPrognostic factorsPrognostic predictorMetabolic therapyMelanoma subtypesMurine modelImmune functionMetabolic gene expressionMelanoma progressionMelanomaSubstrate metabolismMetabolic flux studiesGene expressionGenome AtlasCell lines
2019
SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia
Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer & Metabolism 2019, 7: 10. PMID: 31867105, PMCID: PMC6907191, DOI: 10.1186/s40170-019-0203-1.Peer-Reviewed Original ResearchControlled-release mitochondrial protonophoreInsulin-lowering agentsTumor growthSodium-glucose cotransporter 2 inhibitorsObesity-cancer connectionSustained weight lossCotransporter 2 inhibitorsObesity-associated cancersSubcutaneous insulin infusionInsulin-lowering effectTumor glucose uptakeBreast tumor growthMultiple comparisonsMultiple tumor typesSGLT2 inhibitionSGLT2 inhibitorsObese miceInsulin infusionColon cancer progressionTherapeutic approachesMouse modelBonferroni multiple comparisonsGlucose metabolismColon cancerHyperinsulinemia